The Patent Finder

Volution Immuno Pharmaceuticals SA

5 patents currently held · Updated Nov 18, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Jan 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 22, 2027
    The maintenance fee for Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) (US 11,730,792) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Jun 15, 2027
    The maintenance fee for Method of treating peripheral nerve disorders (US 9,211,312) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 5 of 5

PatentTitleStatus Expires Confidence
US 9,522,171EV576 for use in the treatment of viral infections of the respiratory tract
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,211,312Method of treating peripheral nerve disorders
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,052,129Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,214,602Coversin Variants Lacking C5 Binding
In force
 · High confidence
In forceHigh confidence
US 11,730,792Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 5: 1 patent in force now held by others · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 abandoned · 18 no status recorded

Showing 1 to 10 of 21, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/813,382Coversin for use in the treatment of rheumatic diseasesAug 23, 2024Pending
18/332,191Jun 9, 2023No status recorded
17/569,374Jan 5, 2022No status recorded
17/529,534Nov 18, 2021Abandoned
17/481,528Sep 22, 2021No status recorded
17/333,675May 28, 2021No status recorded
17/244,159Apr 29, 2021No status recorded
17/604,509Mar 4, 2020No status recorded
16/663,655Oct 25, 2019No status recorded
17/761,753Sep 27, 2019No status recorded
10 of 21 applications shown.
Pro members see all 21 published applications.
Pro members: see all 21 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited